Meningitis Vaccine Research Study
Researchers at Emory University are conducting a research study looking at the immune response to a Meningitis B (MenB) vaccine in adults who have previously received a 2-dose Bexsero® MenB primary series at least 2.5 years before enrollment.
Participation is voluntary. You may withdraw at any time.
Fast Facts
2 Doses of the MenB (Bexsero) Vaccine at least 2.5 Years Ago
18-25
Years Old
Compensation
Provided
Conducted in
Atlanta, GA
Study Background
This study is evaluating how the immune system responds to receiving a meningitis B booster vaccine that differs from the brand used in the primary series.
Neisseria meningitidis is a bacterium that causes meningitis (an inflammation of the lining around the brain or spinal cord) and invasive meningococcal disease, requiring treatment in a hospital. Meningococcal infections are very serious and tend to infect young, previously healthy people.
There are two approved vaccines to protect people from meningitis B, Bexsero® and Trumenba®, and another approved vaccine called Penbraya® which protects against 5 different types of meningitis-causing bacteria including meningitis B. Currently, all doses in the primary series and boosters must be from the same brand of meningitis B vaccine. In this study, we want to learn if a booster vaccination with a different meningitis B vaccine can still help provide immunity. This could help respond more quickly to outbreaks and help people who don’t know which meningitis B vaccine they received in the past or can’t access the same one again.
If you are 18-25 years old and received the Bexsero® meningitis B vaccine at least 2.5 years ago, you could be eligible to participate in this important research. Help us learn more about meningitis vaccination by enrolling today!
Study Background
This study is evaluating how the immune system responds to receiving a meningitis B booster vaccine that differs from the brand used in the primary series.
Neisseria meningitidis is a bacterium that causes meningitis (an inflammation of the lining around the brain or spinal cord) and invasive meningococcal disease, requiring treatment in a hospital. Meningococcal infections are very serious and tend to infect young, previously healthy people.
There are two approved vaccines to protect people from meningitis B, Bexsero® and Trumenba®, and another approved vaccine called Penbraya® which protects against 5 different types of meningitis-causing bacteria including meningitis B. Currently, all doses in the primary series and boosters must be from the same brand of meningitis B vaccine. In this study, we want to learn if a booster vaccination with a different meningitis B vaccine can still help provide immunity. This could help respond more quickly to outbreaks and help people who don’t know which meningitis B vaccine they received in the past or can’t access the same one again.
If you are 18-25 years old and received the Bexsero® meningitis B vaccine at least 2.5 years ago, you could be eligible to participate in this important research. Help us learn more about meningitis vaccination by enrolling today!
Additional Information
This study is being done to learn more about how the immune system of young adults (ages 18 to 25 years) responds to a booster dose of a meningitis B vaccine (Trumenba® or Penbraya®) after they previously received a different meningitis B vaccine (Bexsero®) more than 2.5 years ago.
You may be eligible for this study if you meet the following criteria.
Inclusion Criteria:
- Ages 18-25
- Received both doses of the MenB (Bexsero®) vaccine at least 2.5 years ago
- Able to provide proof of prior Bexsero® vaccination
- Generally healthy
- Did not receive more than 2 doses of Bexsero® or any other MenB vaccine(s) (e.g., Trumenba® or Penbraya®)
- Not currently pregnant, breastfeeding, or planning to become pregnant during the study period (up to 2 months)
If you join this study, you will have up to 3 in-person study visits: a screening visit, a vaccine visit, and a follow-up visit. The screening and vaccine visits may be combined. Each visit may last between 30 minutes (i.e., the follow-up visit) and 3 hours (i.e., the vaccine visit).
If you enroll, you would be in this study for about 1 month. If your screening and vaccination visits are on different days, you may be in the study for up to 2 months. You will be asked to provide health information and blood samples, receive one dose of either Trumenba® or Penbraya® (randomly assigned), and return about 1 month later for a follow-up visit and blood draw.
You will only be compensated for the visits that have been completed, and if all study visits are completed you will receive approximately $250.
There is no cost for you to participate in our research study.